Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma.
BACKGROUND
Skin cancers are common, and there has recently been a dramatic increase in their incidence, particularly in the occurrence of melanoma. Furthermore, relapse after curative surgical treatment of melanoma remains a significant clinical challenge and accounts for most of the mortality of this disease.


OBJECTIVE
The aim of this study was to determine whether IMMUNEPOTENT CRP affects B16F10 melanoma cells and tumors growth and vascular endothelial growth factor (VEGF) production in vivo and in vitro.


METHODS
B16F10 cells and B16F10-inoculated mice were treated with different concentrations of IMMUNEPOTENT CRP. Outcomes were then evaluated using MTT, TUNEL, Caspase-3, senescence, ELISA and colorimetric assays. Parameters related to survival and tumor weight were also assessed.


RESULTS
IMMUNEPOTENT CRP decreased the viability of B16F10 cells by increasing apoptosis of the treated cells, and VEGF production was decreased both in vitro and in vivo. Furthermore, treatment prevented metastasis, delayed the appearance of tumors, decreased tumor weight and improved the survival of tumor-bearing mice.


CONCLUSIONS
These observations suggest that IMMUNEPOTENT CRP can be used to suppress growth and metastasis by using targeting proteins such as VEGF.
Franco-Molina
Moisés A
MA
Laboratorio de Inmunología y Virología, Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas de Universidad Autónoma de Nuevo León, San Nicolás de Garza, N L México. moyfranco@hotmail.com
Mendoza-Gamboa
Edgar
E
Zapata-Benavides
Pablo
P
Castillo-Tello
Paloma
P
Isaza-Brando
Clara E
CE
Zamora-Avila
Diana
D
Rivera-Morales
Lydia G
LG
Miranda-Hernández
Diana F
DF
Sierra-Rivera
Crystel A
CA
Vera-García
Magda E
ME
Tamez-Guerra
Reyes S
RS
Rodríguez-Padilla
Cristina
C
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002417:Cattle; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D016922:Cellular Senescence / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D008546:Melanoma, Experimental / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000517:prevention & control; D014165:Transfer Factor / Q000494:pharmacology* / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014165:Transfer Factor; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; C505409:Casp3 protein, mouse; D053148:Caspase 3